Monte Rosa Q3 net loss widens, but revenue increases on Novartis payment
Overview
Monte Rosa Q3 net loss widens to $27.1 mln, driven by increased R&D expenses
Collaboration revenue for Q3 rises to $12.8 mln, up from $9.2 mln year-over-year
Monte Rosa receives $120 mln upfront payment from Novartis, boosting cash reserves
Outlook
Monte Rosa expects MRT-8102 Phase 1 data in H1 2026
Company plans to present MRT-2359 data by year-end 2025
Monte Rosa's cash position expected to fund operations through 2028
Result Drivers
NOVARTIS COLLABORATION - Second agreement with Novartis provides $120 mln upfront payment and potential for up to $5.7 bln in total deal value
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Collaboration Revenue | $12.77 mln | ||
Q3 Net Income | -$27.08 mln | ||
Q3 Operating Expenses | $45.74 mln | ||
Q3 Operating Income | -$32.98 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Monte Rosa Therapeutics Inc is $17.00, about 27.6% above its November 5 closing price of $12.31
Press Release:
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.